CSIMarket


Heron Therapeutics Inc   (HRTX)
Other Ticker:  
 


 

Heron Therapeutics Inc

HRTX's Financial Statements and Analysis



Heron Therapeutics Inc narrowed third quarter of 2023 net loss per share of $-0.17 compare to net loss per share of $-0.38 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.35 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.17 $  31 Mill
$+0.21     $+5M     +17.58 %



Heron Therapeutics Inc 's Revenue rose by 17.58 % in third quarter of 2023 (Sep 30 2023) year on year, to $31 million and declined by -1.69 % sequentially.


Heron Therapeutics Inc is

More on HRTX's Income Statement



Heron Therapeutics Inc in the third quarter of 2023 recorded net loss of $-25.008 million, an improvement compare to net loss of $-41.908 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-42.059 million realized in previous quarter.

More on HRTX's Growth

Heron Therapeutics Inc Inventories
Inventories declined by -19.59 % to $42.01 million from III. Quarter a year ago, sequentially inventories fell by -5.86 %. HRTX's Cash flow In the third quarter of 2023 company's net cash flow was $21 million, capital expenditures fell by -0.0451,662.22%, to $-1 millions compare to same quarter a year ago

More on HRTX's Cash flow Statement


Heron Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Heron Therapeutics Inc payed $ -0.68 cash per share, on a free-cash flow basis .


Tangible Book value grew to $ -0.19 per share from $ -0.33.

Company issued 25.27 million shares or 21.11 % in Sep 30 2023.


More on HRTX's Dividends

 Market Capitalization (Millions) 499
 Shares Outstanding (Millions) 145
 Total Debt (Millions $) 149
 Revenue (TTM) (Millions $) 123
 Net Income (TTM) (Millions $) -120
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) -2
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 336




Heron Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Heron Therapeutics Inc had negative $ -0.68 cash flow per share, on a free-cash flow basis .


Tangible Book value grew to $ -0.19 per share from $ -0.33.

Company issued 25.27 million shares or 21.11 % in Sep 30 2023.


More on HRTX's Balance Sheets

 Market Capitalization (Millions) 499
 Shares Outstanding (Millions) 145
 Total Debt (Millions $) 149
 Revenue (TTM) (Millions $) 123
 Net Income (TTM) (Millions $) -120
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) -2
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 336
   


  News about Heron Therapeutics Inc Earnings

Heron Therapeutics Inc: Unraveling the Mystery Behind Its Recent Stock Decline and Exploring Key Financial Metrics



In the ever-evolving world of finance, keeping track of a company's performance is crucial for investors and industry analysts. One such company that has experienced notable changes in recent trading sessions is Heron Therapeutics Inc. This article aims to shed light on the stock's recent decline, year-to-date performance, and provide an overview of the key financial metrics for the company.
Declining Stock Performance:
Over the course of the last five trading days, Heron Therapeutics Inc's stock experienced a significant downturn, falling by -20.89%. This decline adds to its year-to-date performance, which currently stands at -75.91%. Such a drop raises concerns among investors and undersc...

Heron Therapeutics Inc Faces Persistent Losses with a Shortfall of $-0.35 per Share Despite Revenue Growth in April-June 2023 Period

Heron Therapeutics Inc (HR...

1. Heron Therapeutics Inc. Generates Impressive Revenue Surge, but Profitability Eludes in Recent Fiscal Period

Heron Therapeutics Inc., a major pharmaceutical preparations company, recently announced in their first quarter financial report for 2023 that they experienced a surge in revenue by 26.252% to $29.62 million compared to the same period from the previous year. While this may seem like positive news, it?s important to note that the company lost money at $-0.27 per share. This is a significant increase in deficit from the preceding period which was $-0.15 per share, and their revenue also decreased by -1.375% from $30.03 million.
Despite the significant loss in earnings per share, Heron Therapeutics remains focused on improving their expansion prospects by increasing expenditures, while also trying to offse...


Date modified: 2023-11-16T18:35:59+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com